PD-L1在肺大细胞神经内分泌癌中的表达和预后相关性及文献回顾

黄伟业; 王千毓; 何娇; 罗陆侨

doi:10.12019/j.issn.1671-5144.2021.06.010

PD-L1在肺大细胞神经内分泌癌中的表达和预后相关性及文献回顾

1.
广东省人民医院病理科、广东省医学科学院, 广州 510080
2.
广州医科大学附属肿瘤医院放疗科, 广州 510095

基金项目: 广东省医学科学技术研究基金项目（A2021227）

详细信息

作者简介:
黄伟业（1987-）,男,广东佛山人,病理技师,医学硕士,从事病理技术在肿瘤诊断中应用的研究。

通讯作者:
罗陆侨, Tel: 020-83827812, E-mail: 332401288@qq.com。

中图分类号: R734.2
计量
- 文章访问数: 219
- HTML全文浏览量: 2
- PDF下载量: 114
出版历程
- 收稿日期: 2021-10-08
- 发布日期: 2021-12-27

Association of PD-L1 Expression With Survival in Large Cell Neuroendocrine Lung Carcinoma and Literature Review

1.
Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
2.
Department of Radiotherapy, Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou 510095, China

摘要

摘要: 目的分析肺大细胞神经内分泌癌（large cell neuroendocrine lung carcinoma,LCNEC）中程序性死亡配体-1（programmed death ligand-1,PD-L1）的表达及其与预后的相关性,同时进行相关文献回顾。方法回顾性收集2016年1月至2021年7月期间于广东省人民医院病理科诊断为LCNEC并行PD-L1检测的患者42例,同时收集患者PD-L1检测结果、临床病理特征和预后数据,分析患者的PD-L1表达以及与临床病理特征和预后的相关性。通过PubMed检索LCNEC中PD-L1表达的相关研究报道。结果 42例患者的中位年龄63岁,男性占85.7%,有吸烟史的患者占42.9%,手术切除标本占81%,标本中47.6%是纯大细胞神经内分泌癌,其余为复合性大细胞神经内分泌癌,复合成分为小细胞癌、腺癌或鳞癌。使用22C3或SP142抗体克隆行PD-L1检测,其中22C3抗体染色阳性率43.2%,SP142抗体阳性率60%,总体阳性率为45.2%。接受根治性手术的PD-L1阳性患者的无疾病生存期（disease-free survival,DFS）显著优于PD-L1阴性患者,然而整体的总生存期（overall survival,OS）未显示明显的差异。Cox回归分析显示PD-L1与DFS、OS均未见显著相关性。文献回顾11篇相关研究报道,共计713例病例,PD-L1表达的阳性率为10.4%~100%,免疫细胞的阳性率均高于肿瘤细胞,并且免疫细胞的阳性往往与更好的预后相关,而肿瘤细胞阳性在不同的研究中出现了相矛盾的预后相关性。结论 LCNEC患者中部分表达PD-L1,并且PD-L1阳性患者具有更长的DFS。
- 肺大细胞神经内分泌癌 /
- PD-L1 /
- 免疫治疗
Abstract: Objective To ascertain the expression of programmed death ligand-1 （PD-L1） on large cell neuroendocrine lung carcinoma （LCNEC）, analysis its association with survival and review existing literatures. Methods Between January 2016 to July 2021, 42 LCNEC patients diagnosed at Department of pathology, Guangdong Provincial People's Hospital with PD-L1 detection were included. PD-L1 expression was analyzed by immunohistochemistry and the association of PD-L1 expression with clinicopathological characteristics and survival were performed. Previously published studies using PubMed search engine were reviewed. Results Forty-two cases of LCNECs were retrieved. Median age was 63 years with male preponderance （85.7%）. Nearly half of patients （42.9%） were smoker. 81% of the specimens were from surgical resection. 47.6% were diagnosed with pure LCNECs and the others were combined LCNECs with small cell lung cancer, adenocarcinoma and squamous carcinoma. Immunostaining of PD-L1 was performed using clone 22C3 with the percentage positivity of 43.2% or SP142 with the percentage positivity of 60% and the overall percentage positivity was 45.2%. Patients with PD-L1 positive showed significantly longer disease-free survival （DFS） but not overall survival （OS） than those with PD-L1 negative, but in Cox regression analysis, PD-L1 was not associated with either DFS or OS. Eleven studies evaluating 713 LCNECs were reviewed. The percentage positivity varied from 10.4%~100%, which was higher in immune cells than that in tumor cells. Moreover, PD-L1 positivity in immune cells was associated with better prognosis, while the association of PD-L1 positivity in tumor cells with prognosis was still inconsistent. Conclusions PD-L1 positivity could be found in part of LCNECs, and DFS in patients with PD-L1 positive tends to be longer.
- large cell neuroendocrine lung carcinoma /
- programmed death ligand-1 （PD-L1） /
- immunotherapy

HTML全文

参考文献(26)

[1]	SIEGEL R L, MILLER K D, JEMAL A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30.
[2]	CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[3]	MENGOLI M C, LONGO F R, FRAGGETTA F, et al.The 2015 World Health Organization Classification of lung tumors: New entities since the 2004 Classification[J]. Pathologica, 2018, 110(1):39-67.
[4]	FISCH D, BOZORGMEHR F, KAZDAL D, et al.Comprehensive dissection of treatment patterns and outcome for patients with metastatic large-cell neuroendocrine lung carcinoma[J]. Front Oncol, 2021, 11:673901.
[5]	SHERMAN S, ROTEM O, SHOCHAT T, et al.Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)[J]. Lung Cancer, 2020, 143:40-46.
[6]	CHAUHAN A, ARNOLD S M, KOLESAR J, et al.Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: Current status[J]. Oncotarget, 2018, 9(18):14738-14740.
[7]	LEVRA M G, MAZIERES J, VALETTE C A, et al.P1.07-012 Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: Results from a French retrospective cohort[J]. J Thorac Oncol, 2017, 12(1):S702-S703.
[8]	LUO X L, LUO L Q, H J, et al. Effects of immunohistochemical conditions on the results of PD-L1 (22C3) staining[J]. Chinese Journal of Pathology, 2021, 49(11): 6. [骆新兰, 罗陆侨, 何娇, 等. 免疫组织化学检测条件对PD-L1(22C3)染色结果的影响[J]. 中华病理学杂志, 2021,49(11):6. ]
[9]	TSURUOKA K, HORINOUCHI H, GOTO Y, et al.PD-L1 expression in neuroendocrine tumors of the lung[J]. Lung Cancer, 2017,108:115-120.
[10]	INAMURA K, YOKOUCHI Y, KOBAYASHI M, et al.Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor[J]. Cancer Med, 2017,6(10):2347-2356.
[11]	OHTAKI Y, KAIRA K, ATSUMI J, et al.Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung[J]. Am J Transl Res, 2018,10(10):3243-3253.
[12]	BAINE M K, REKHTMAN N.Multiple faces of pulmonary large cell neuroendocrine carcinoma: Update with a focus on practical approach to diagnosis[J]. Transl Lung Cancer Res, 2020,9(3):860-878.
[13]	ARPIN D, CHARPENTIER M C, BERNARDI M, et al.PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: Potential implications for use of immunotherapy in these patients: The GFPC 03-2017 “EPNEC” study[J]. Ther Adv Med Oncol, 2020, 12:1758835920937972.
[14]	DERKS J L, VAN SUYLEN R J, THUNNISSEN E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: Does the regimen matter?[J]. Eur Respir J, 2017, 49(6):1601838.
[15]	THUNNISSEN E, BORCZUK A C, FLIEDER D B, et al.The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases[J]. J Thorac Oncol, 2017,12(2):334-346.
[16]	LINDSAY C R, SHAW E C, MOORE D A, et al.Large cell neuroendocrine lung carcinoma: Consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists[J]. Br J Cancer, 2021, 125(9):1210-1216.
[17]	FAN Y, MA K, WANG C, et al.Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors[J]. Onco Targets Ther, 2016, 9:6075-6082.
[18]	ISHII H, AZUMA K, KAWAHARA A, et al.Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer[J]. J Thorac Oncol, 2015,10(3):426-430.
[19]	TSAO M S, KERR K M, KOCKX M, et al.PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of blueprint phase 2 project[J]. J Thorac Oncol, 2018,13(9):1302-1311.
[20]	WANG H, LI Z, DONG B, et al.Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors[J]. Diagn Pathol, 2018,13(1):30.
[21]	GULERIA P, KUMAR S, MALIK P S, et al.PD-L1 Expression in small cell and large cell neuroendocrine carcinomas of lung: An immunohistochemical study with review of literature[J]. Pathol Oncol Res, 2020,26(4):2363-2370.
[22]	HERMANS B C M, DERKS J L, THUNNISSEN E, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)[J]. Lung Cancer, 2019,130:179-186.
[23]	REKHTMAN N, PIETANZA M C, HELLMANN M D, et al.Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets[J]. Clin Cancer Res, 2016,22(14):3618-3629.
[24]	KIM H S, LEE J H, NAM S J, et al.Association of PD-L1 Expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung[J]. J Thorac Oncol, 2018,13(5):636-648.
[25]	KASAJIMA A, ISHIKAWA Y, IWATA A, et al.Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors[J]. Endocr Relat Cancer, 2018,25(3): 339-350.
[26]	EICHHORN F, HARMS A, WARTH A, et al.PD-L1 expression in large cell neuroendocrine carcinoma of the lung[J]. Lung Cancer, 2018,118:76-82.

施引文献(3)

期刊类型引用(2)

1.	王艳，徐凤霞，段玮，曾海珠，刘倩倩，王玉芳，刘兴晖. 蛋白质精氨酸甲基转移酶5和PD-L1在非小细胞肺癌组织中的表达及其对预后的评估价值. 标记免疫分析与临床. 2023(04): 578-582+694 . 百度学术
2.	吕田园，张新峰，王怀璋，唐玉君，苏珊珊，王翠翠. 晚期肺大细胞神经内分泌癌的临床治疗研究进展. 中国癌症防治杂志. 2022(05): 593-599 . 百度学术